Member Info for Kong1

Art123

Appolisher@hotmail.com

Email me and I’ll send reply

Art123

I have recieved this morning a further email from the investor relations, that GS20 trading platform is indeed live and generating money on each transaction.

There are no fixed rates and the commission that GS20 recieved from each trade is variable all depending on circumstances.

So yes GS20 are generating money on transactions that’s official

Massive ray you can’t post screenshots on here

Hi emailed the investor relations people today asking if the platform is live.

Their reply was indeed it is !!!

So the platform

Is live, I hope this puts everything to bed once and got all

Not sure if this has been posted before

http://obdx.co/ProstateQA

Clungseeker

rapidly expanding your business creates many problems.

How the business gets over these is down to how good the management are in dealing with the situation.

Hiring new staff and getting the correct staff is hard. There is a cost to the company, in helping new staff working to the procedures of the company.

There is also a strain on the companies capital and cash flow. It will take 4-6 months for the companies cash flow to stabilise providing the management can work through this time of expansion.

Now i`m not trying to knock the company in anyway, but rapid expansion has a cost and it has to be managed, and managed correctly.

Turnover is vanity, profit is sanity.

We wont know how good the management are for another several months, when the figures show what this period was like as a productive one or not for Petrofac.

"Carillion’s business model was an unsustainable dash for cash. The mystery is not that it collapsed, but how it kept going for so long. Carillion’s acquisitions lacked a coherent strategy beyond removing competitors from the market, yet failed to generate higher margins. Purchases were funded through rising debt and stored up pensions problems for the future. Similarly, expansions into overseas markets were driven by optimism rather than any strategic expertise. Carillion’s directors blamed a few rogue contracts in alien business environments, such as with Msheireb Properties in Qatar, for the company’s demise. But if they had had their way, they would have won 13 contracts in that country. The truth is that, in acquisitions, debt and international expansion, Carillion became increasingly reckless in the pursuit of growth. In doing so, it had scant regard for long-term sustainability or the impact on employees, pensioners and suppliers."

The Model PFC are following..........

The bead counters greed was Carillions downfall.........

You can shout at snapper all you want but the above is pretty good and close to the truth.

don`t get caught up in all the hype. due dilligence and common sense are needed every now and then.

GLA and do your own homeworrk

It makes you wonder why a person has posted so many times over time, not one post is positive all are negative, and yet he is still here.

A normal person would simply not post if he didn`t like the company.

so obviously the person has issues ,

time to filter out some more trash

Well done NU

Some serious big hitters there in what ever form they are looking at

Should see some uplift from here

Hi tricky

we could be well positioned tommorrow, should get a lift if this buyer has done

Tricky

an eventful day but we went down

Timster my wording of trial was supposed to mean what you put here, so sorry for the confusion

The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA).

I think Results from cohort 7, will trigger the application for the fortnightly trial.

Hard data from all the cohorts will catapult Avacta and give BP the information which they want.

Up until now, proof was needed. The data should give them this.

Once this data is out and hopefully more efficacy news, the BP`s will want to move in quite quickly and tie up any deals going forward into the next phases.

I would suspect the fear of not partnering Avacta will hasten a lucatrive deal and one that should be in Avacta`s favour as I see all the aces are in their hands.

Kong

Bigblindbandy

AS stated on the 28th sept that cohort 7 had started, so if we use that date then the last dose should be administered on Wednesday.

If as you say they could have started on the 20th then the patients have already been given their third and final dose.

How long afterwards they may wait for the data or to see how much the tumour shrinks is anybodys guess.

But yes news is possible from next week on.

If we get similar safety news as from previous cohorts and favourable tumour shrinkages.

Then I would say big pharmas will be all over Avacta like a cheap Italian suit.

Lucrative partnering news will be around the corner

Regarding the approval of the 2 weekly study.

I suspect they are waiting for data on the standard 3 weekly trial on cohort 7

If all good, it will be rubber stamped

Each bit of positive news will move the SP.

Positive data will move the SP

Positive results from cohort 7 will move the SP

News we can dose fortnightly, will move the SP

Start of P2 trial will

And licensing deals will certainly move the SP

That’s what will move the SP

Something is bubbling

RE: Fireworks around Bonfire Night?Today 09:12

I believe that the fastest cohort so far completed in 60 days. Based on that, the earliest C7 could be expected to finish would be the week of Nov. 20th. Before that I would expect news on the FDA decision on the bi-weekly dosing.

Jiveturkey

AS mentioned in the podcast on the 28th sept, that the first patients had already been dosed in cohort 7.

so if we said first patient was dosed on the 28th, ( but I suspect earlier ) the 3rd dose could be given on the 9th november !

news could be forthcoming from around this date onwards.

Hi wiggly

I think the data will take a little longer to come out.

I’m suspecting another 4 - 6 weeks.

AS mentioned that they wanted to include some data from cohort 7, hence my thinking behind how long it may be.

Also AS will be getting some data out within the next 8 days about Affimers as he mentioned there is a cancer convention starting on the 11th which they are attending.

He is focused on the Affimers data for this.

None the less the run up to Xmas is going to be informative.

Data on cohorts

Possible lucatrive partnerships

results from cohort 7

News on P2 trial

Sp should rise on the back of all this. Very exciting times around the corner for all

Kong

It’s been a great week, not only for the shareprice but for the fight against cancer.

I’m hoping we may get some news on Thursday. if the previous patients mentioned in the agm from cohorts 2. 3 and 4 are still recieving treatments and if patients from cohorts 5 & 6 are still receiving treatment

It would be very interesting to know